Share Search
Visit the Share Search
Silence Therapeutics begins dosing in lipoprotein treatment trial
17th Feb 2021 08:12
(Sharecast News) - Silence Therapeutics has started dosing subjects in the 'APOLLO' phase 1 clinical study of its wholly-owned lead product candidate 'SLN360', it announced on Wednesday, for the treatment of elevated lipoprotein-a (Lp(a)) levels.
The AIM-traded firm said the first-in-human study was investigating the safety, tolerability, pharmacokinetic and pharmacodynamic response of SLN360 in people with elevated Lp(a) levels of at least 60 milligrams per decilitre.
"The APOLLO trial is a global, randomized, double-blind, placebo controlled, single-ascending and multiple-ascending dose study enrolling approximately 88 subjects total in up to nine cohorts," the Silence board explained in its statement.
The company said it intended to report data from the single-ascending dose portion of the study in the second half of the year.
At 1044 GMT, shares in Silence Therapeutics were down 1.32% at 600p.
The AIM-traded firm said the first-in-human study was investigating the safety, tolerability, pharmacokinetic and pharmacodynamic response of SLN360 in people with elevated Lp(a) levels of at least 60 milligrams per decilitre.
"The APOLLO trial is a global, randomized, double-blind, placebo controlled, single-ascending and multiple-ascending dose study enrolling approximately 88 subjects total in up to nine cohorts," the Silence board explained in its statement.
The company said it intended to report data from the single-ascending dose portion of the study in the second half of the year.
At 1044 GMT, shares in Silence Therapeutics were down 1.32% at 600p.